Publications

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

ESMO open

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

01-10-2023

Cellular and molecular life sciences : CMLS

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

14-08-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Virchows Archiv : an international journal of pathology

Reliability of whole mount radical prostatectomy histopathology as the ground truth for artificial intelligence assisted prostate imaging.

01-08-2023

Bioinformatics advances

snHiC: a complete and simplified snakemake pipeline for grouped Hi-C data analysis.

03-07-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Authors' reply-A sensitivity analysis of the RAPIDO clinical trial.

01-04-2023

ESMO open

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

01-04-2023

Cancers

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

28-02-2023

Proceedings of the National Academy of Sciences of the United States of America

Mammalian life depends on two distinct pathways of DNA damage tolerance.

24-01-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Cancer research

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

02-11-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

Nucleic acids research

Double-strand break toxicity is chromatin context independent.

23-09-2022

Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

Nature genetics

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.

01-09-2022

Nucleic acids research

HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.

12-08-2022

Nature communications

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation.

02-08-2022

NPJ breast cancer

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

06-05-2022

Key Publication

Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022

EMBO reports

Unexpected gene activation following CRISPR-Cas9-mediated genome editing.

03-02-2022

Prostate cancer and prostatic diseases

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

01-02-2022

Cancers

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

16-12-2021

Cell reports

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

14-12-2021

Nature communications

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

04-11-2021

NPJ breast cancer

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

20-10-2021

Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021

Nature cell biology

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

01-09-2021

Cancers

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

27-08-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

Cells

TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication.

16-06-2021

Endocrine-related cancer

Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?

11-05-2021

Genome biology

Functional mapping of androgen receptor enhancer activity.

11-05-2021

Nucleic acids research

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites.

19-04-2021

Molecular aspects of medicine

Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.

01-04-2021

NPJ breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

22-03-2021

Nature communications

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.

02-02-2021

Nature medicine

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

01-02-2021

Nature reviews. Urology

Genomic and phenotypic heterogeneity in prostate cancer.

01-02-2021

Nature communications

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

15-01-2021

Cancer cell

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.

14-09-2020

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020

Key Publication

International journal of cancer

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

15-08-2020

Breast cancer research : BCR

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

11-08-2020

Nature genetics

The DNA methylation landscape of advanced prostate cancer.

01-08-2020

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

Reliability of whole mount radical prostatectomy histopathology as the ground truth for artificial intelligence assisted prostate imaging.

snHiC: a complete and simplified snakemake pipeline for grouped Hi-C data analysis.

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

Authors' reply-A sensitivity analysis of the RAPIDO clinical trial.

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

Mammalian life depends on two distinct pathways of DNA damage tolerance.

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

Double-strand break toxicity is chromatin context independent.

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.

HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation.

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

Unexpected gene activation following CRISPR-Cas9-mediated genome editing.

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication.

Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?

Functional mapping of androgen receptor enhancer activity.

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites.

Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Genomic and phenotypic heterogeneity in prostate cancer.

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

The DNA methylation landscape of advanced prostate cancer.

This site uses cookies